MetLife (MET) Aandelenoverzicht
MetLife, Inc., een financiële dienstverlener, biedt wereldwijd diensten aan op het gebied van verzekeringen, lijfrentes, employee benefits en vermogensbeheer. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 5/6 |
MET Community Fair Values
Create NarrativeSee what 48 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MetLife, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$84.30 |
| 52 Week Hoogtepunt | US$84.38 |
| 52 Week Laag | US$67.33 |
| Bèta | 0.77 |
| 1 maand verandering | 8.80% |
| 3 maanden verandering | 6.57% |
| 1 Jaar Verandering | 8.55% |
| 3 jaar verandering | 59.75% |
| 5 jaar verandering | 28.39% |
| Verandering sinds IPO | 471.53% |
Recent nieuws en updates
Recent updates
MET: Share Repurchases And Dividend Increases Will Support Future Upside Potential
Analysts have slightly adjusted their fair value estimate for MetLife, nudging the implied price target from about $89.06 to $89.31. This reflects modest tweaks to assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiples.MetLife: A Great Time To Buy The Preferred Stock
Summary MetLife preferred shares now yield over 6% as rising rates pressure prices, offering attractive risk/reward for long-term investors. MET's preferred dividends are well covered, with payout ratios under 4% of adjusted earnings and likely dropping to 3% as EPS grows. Series F preferred, MET.PR.F, trades at ~$19.25 for a 6.15% yield. Low payout ratio and strong balance sheet support continued payments. Double-digit adjusted EPS growth and 15–17% ROE guidance suggest MET common shares also offer compelling upside below $80/share. Read the full article on Seeking AlphaMET: Share Repurchases Following Index Exit Will Support Future Upside Potential
Analysts have slightly reduced their MetLife fair value estimate to $89.06 from $90.50, reflecting minor adjustments to assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio that refine their outlook for the shares. What's in the News MetLife has been dropped from the S&P 100 index, which may influence how some index funds and benchmarks gain exposure to the stock (Key Developments).MET: Share Repurchases And Index Exit Will Shape Future Upside Potential
Analysts have trimmed their average MetLife price target slightly to $90.50 from $90.73, citing updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News MetLife, Inc.MET: Share Repurchases Will Support Future Upside Potential
Analysts have slightly adjusted their price target for MetLife to $90.73 from $90.93, reflecting updated views on discount rates, revenue growth, profit margins, and future price-to-earnings (P/E) assumptions. What's in the News MetLife reported that from October 1, 2025 to January 31, 2026 it repurchased 7,608,263 shares, representing 1.15% of shares, for a total of US$600 million under its current buyback program (Key Developments).MET: Buybacks And Retirement Income Agreements Will Drive Future Upside
Analysts have trimmed their price target on MetLife to about $90.93 from roughly $92.93. This reflects updated views on slightly lower expected revenue growth, a modestly softer profit margin, a higher discount rate, and a largely unchanged future P/E assumption.MET: Retirement Income Agreements Will Drive Future Upside In Earnings Power
Analysts have marginally reduced their price target on MetLife to approximately 92.93 dollars from 93 dollars, citing a slightly higher assumed discount rate. This more than offsets modest improvements in forecast profit margins and valuation multiples.MET: Revenue Will Advance On New Retirement Income And Employee Support Agreements
Analysts have slightly reduced their price target for MetLife from $93.33 to $93.00, reflecting minor adjustments to discount rate and profit margin assumptions. They maintain a positive outlook on revenue growth.Digital Expansion And Employee Support Benefits Will Drive Outperformance Ahead
Analysts have modestly raised their price target for MetLife, increasing it from $93.00 to $93.33 per share. They cited slight improvements in projected revenue growth and profit margins as the reason for the adjustment.International Demand And Digital Transformation Will Fuel Success
Analysts have raised their fair value estimate for MetLife from $91.86 to $93.00. This reflects slight adjustments to discount rates and growth assumptions.International Demand And Digital Transformation Will Fuel Success
With no change in revenue growth forecasts or discount rate, MetLife’s fair value estimate remains steady at $91.86. What's in the News MetLife will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, at $1,000 per share; dividends of $19.250 per share will be paid separately, and all further dividends cease post-redemption.It's Unlikely That MetLife, Inc.'s (NYSE:MET) CEO Will See A Huge Pay Rise This Year
Key Insights MetLife's Annual General Meeting to take place on 17th of June Salary of US$1.50m is part of CEO Michel...MetLife: Double-Digit EPS Growth With A Single-Digit P/E, Strong Chart
Summary MetLife, Inc. is rated a buy due to its solid value, above-market dividend yield, and favorable technical chart despite recent earnings misses. Insurance stocks, including MET, have lagged behind the Financials sector and S&P 500, with premium increases expected to slow as consumers react to rising costs. MET's 2025 outlook is positive, with analysts forecasting over 17% EPS growth and 5%-6% revenue growth, despite recent underperformance in certain segments. Key risks include lower stock prices, falling interest rates, and regulatory challenges, but MET's strong investment income and share buybacks are positive factors. Read the full article on Seeking AlphaMetLife Upgraded To Buy As Financials And Insurance Show Further Upside Potential
Summary MetLife stock gets upgraded to a buy, from my prior hold rating, as indicators point to further share price potential in the financials sector, as well as the insurance subsector. Data points to future continued demand for annuities and life insurance, and MetLife has in Q3 achieved new organic customer growth in 2 key businesses. Although its dividend yield is not stellar vs. peers, it has a 10-year track record of proven dividend growth, something it has potential to continue. Even though it is trading at a 10-year high, it remains undervalued on P/E and EV/EBITDA vs. peers, so continues to present a buy opportunity. Read the full article on Seeking AlphaMetLife: One Of The Best Life Insurance Stocks
Summary MetLife's strong financial performance, with a 17.5% increase in adjusted EPS and a 15.2% rise in book value, makes it an attractive investment. Despite comparable performance to Aflac, MetLife's lower valuation offers better value for shareholders. MetLife's growing dividend yield and robust share buyback program enhance shareholder value, with ample cash reserves supporting future buybacks. Risks include potential commercial real estate portfolio defaults and market volatility, but MetLife's strong fundamentals and attractive valuation make it a compelling choice. Read the full article on Seeking AlphaHigher For Longer? Consider MetLife's Preferred Shares With A 6.6% Yield
Summary MetLife's preferred shares, particularly the Series A with floating dividends, offer potential for investors in a 'higher for longer' inflation and interest rate environment. MetLife's strong financial performance in Q1 2021, with net profit covering preferred dividends by less than 8%. Series A preferred shares have a minimum 4% floor for dividends, with potential for higher yields based on 3 month SOFR rate adjustments. Read the full article on Seeking AlphaMetLife Looks Like An Undervalued Property In An Unpopular Neighborhood
Summary MetLife shares have outperformed peers, but life insurance stocks have not really been in favor given concerns about CRE losses and rate cuts. Higher rates have allowed MetLife to reprice its investment portfolio at higher rates and sell more spread products, and the benefits will last even as rates fall. There are understandable concerns about MetLife's CRE exposure (office in particular), as the insurer is overweight here, but losses will take years to materialize and can be absorbed. MetLife's focus on profitable core businesses like group life and health, pension risk transfer, and international markets should lead to steady growth and returns for investors. This is something of a contrarian call given weak sector sentiment, but MetLife's differentiated model and ability to out-earn its cost of equity should drive outperformance. Read the full article on Seeking AlphaMetLife: Healthy But Lacks Clear Advantages
Summary MetLife has experienced a decade of light shrinking instead of growth. This started as early as 2015 and was attributed to increased competition and a decrease in annuity sales, but this never seemed to improve. With their current size, competitive hurdles, and lack of clear targets for growth internationally, shares of MET will likely only give mediocre returns at best. Read the full article on Seeking AlphaRendement voor aandeelhouders
| MET | US Insurance | US Markt | |
|---|---|---|---|
| 7D | 6.5% | 2.5% | -0.8% |
| 1Y | 8.6% | -6.1% | 27.1% |
Rendement versus industrie: MET overtrof de US Insurance industrie, die het afgelopen jaar een rendement -6.1 % opleverde.
Rendement versus markt: MET presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 27.1 % opleverde.
Prijsvolatiliteit
| MET volatility | |
|---|---|
| MET Average Weekly Movement | 3.6% |
| Insurance Industry Average Movement | 4.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: MET heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van MET is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1999 | 46,000 | Michel Khalaf | www.metlife.com |
MetLife, Inc., een financiële dienstverlener, biedt wereldwijd diensten aan op het gebied van verzekeringen, lijfrentes, employee benefits en vermogensbeheer. Het bedrijf is actief in zes segmenten: Group Benefits; Retirement and Income Solutions; Azië; Latijns-Amerika; Europa, het Midden-Oosten en Afrika; en MetLife Holdings. Het bedrijf biedt levensverzekeringen, tandverzekeringen, collectieve arbeidsongeschiktheidsverzekeringen op korte en lange termijn, betaald verlof voor gezins- en medische zorg, individuele arbeidsongeschiktheidsverzekeringen, ongevallen- en ziektekostenverzekeringen, zichtverzekeringen en huisdierverzekeringen, evenals prepaid juridische plannen; regelingen voor werkgevers die alleen administratieve diensten leveren; en algemene en aparte rekeningverzekeringen en synthetische contracten met gegarandeerde rente, evenals private financieringsovereenkomsten met variabele rente.
MetLife, Inc. Samenvatting
| MET fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$53.09b |
| Inkomsten(TTM) | US$3.43b |
| Inkomsten(TTM) | US$77.58b |
Is MET overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MET resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$77.58b |
| Kosten van inkomsten | US$59.15b |
| Brutowinst | US$18.43b |
| Overige uitgaven | US$15.00b |
| Inkomsten | US$3.43b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 5.34 |
| Brutomarge | 23.75% |
| Nettowinstmarge | 4.43% |
| Schuld/Eigen Vermogen Verhouding | 178.0% |
Hoe presteerde MET op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
Betaalt MET een betrouwbaar dividend?
Zie MET dividendgeschiedenis en benchmarks| MetLife dividenddata | |
|---|---|
| Ex Dividend Datum | May 12 2026 |
| Betaaldatum dividend | Jun 09 2026 |
| Dagen tot Ex-dividend | 11 days |
| Dagen tot dividendbetaaldatum | 17 days |
Betaalt MET een betrouwbaar dividend?
Zie MET dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 14:04 |
| Aandelenkoers aan het einde van de dag | 2026/05/21 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
MetLife, Inc. wordt gevolgd door 32 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jacob Kilstein | Argus Research Company |
| Jay Gelb | Barclays |
| Taylor Scott | Barclays |